Hyperhidrosis Treatment Global Market Report 2024

The hyperhidrosis treatment market size has grown strongly in recent years. It will grow from $1.48 billion in 2023 to $1.58 billion in 2024 at a compound annual growth rate (CAGR) of 7.0%. The observed growth in the historic period for hyperhidrosis treatments can be attributed to several factors. These include increased awareness of cosmetic concerns related to excessive sweating, growing recognition of the psychosocial impact of hyperhidrosis, and regulatory support for addressing this medical condition. These factors collectively contributed to the heightened interest and utilization of treatments to manage hyperhidrosis symptoms during the historic period.

The hyperhidrosis treatment market size is expected to see strong growth in the next few years. It will grow to $1.99 billion in 2028 at a compound annual growth rate (CAGR) of 5.9%. The anticipated growth in the forecast period for hyperhidrosis treatments can be attributed to several factors. These include a shift towards patient-centric treatment approaches, increased global health awareness, advancements in topical therapies, innovations in surgical procedures, and the integration of hyperhidrosis treatments into comprehensive dermatology practices. Major trends expected in the forecast period include the adoption of personalized treatment approaches tailored to individual patient needs, technological innovations in medical devices used for hyperhidrosis treatment, ongoing research and development in oral medications targeting excessive sweating, the use of telemedicine for consultations and follow-ups, and increased collaborations and partnerships within the healthcare industry.

The anticipated rise in the occurrence of diabetes mellitus is poised to drive the expansion of the hyperhidrosis treatment market. Diabetes mellitus, characterized by abnormal insulin levels leading to high blood sugar levels, can affect the nervous system controlling sweat glands, resulting in excessive sweating or hyperhidrosis. This medical condition's impact on sweat regulation and body temperature maintenance can contribute to hyperhidrosis. For example, data from the International Diabetes Federation in December 2021 highlighted that 537 million adults between 20 to 79 years old were affected by diabetes in 2021, projecting an increase to 643 million by 2030 and an estimated 783 million by 2045. Thus, the escalating prevalence of diabetes mellitus is a significant driver for the hyperhidrosis treatment market.

The upward trend in healthcare expenditures is anticipated to fuel the growth of the hyperhidrosis treatment market. Healthcare expenditure encompasses spending on various medical services, including treatment, equipment, medication, and preventive care. The surge in healthcare expenditure has brought about heightened awareness regarding hyperhidrosis and its impact on individuals' daily routines and quality of life. This increased awareness has led to the development of new treatment methods, surgical interventions, and considerations for associated health conditions. For instance, a report by the UK's Office for National Statistics indicated a 9.4% nominal and 9.7% real-term increase in healthcare spending between 2020 and 2021. Specifically, preventive care expenditure surged to $45.72 billion in 2021, doubling from the previous year. Consequently, the escalating healthcare expenditures are propelling growth within the hyperhidrosis treatment market.

The exorbitant expense associated with hyperhidrosis treatment significantly hampers the expansion of the hyperhidrosis treatment market. The high cost of treatment poses a significant barrier to access for many patients, potentially restricting their ability to pursue available treatment options. This financial burden may limit market growth, as individuals facing hyperhidrosis may find themselves unable to afford the necessary treatments. For example, statistics from The American Society for Aesthetic Plastic Surgery indicated that the average cost of hyperhidrosis treatment in 2021 was $1,193, marking a 19% increase from the previous year. Thus, the elevated cost of hyperhidrosis treatment stands as a deterrent to the market's growth.

Key players within the hyperhidrosis treatment market are intensifying their efforts to introduce wipe formulations, strategically aiming to boost market revenues. Wipe formulations serve as a delivery method for applying medications or antiperspirants to the skin through pre-moistened wipes. These formulations effectively apply antiperspirant medication to alleviate excessive sweating. An illustration of this strategy can be seen with Maruho Co. Ltd.'s May 2022 launch of Rapifort Wipes 2.5% in Japan. These wipes feature glycopyrronium tosilate hydrate as an active component, reducing sweat production by impeding the activation of acetylcholine receptors in sweat glands. Application of this medication solution once daily to both underarms with a single-use non-woven cloth in each packet minimizes sweating. This convenient, hygienic single-use wipe addresses primary axillary hyperhidrosis, a condition characterized by unexplained excessive underarm sweating that can disrupt daily activities.

In June 2023, miraDry Inc., a United States-based company specializing in non-invasive hyperhidrosis treatment, entered into a partnership with the International Hyperhidrosis Society (IHhS). This collaboration is designed to facilitate cooperation between miraDry and the International Hyperhidrosis Society (IHhS) in order to enhance hyperhidrosis therapy. The partnership underscores miraDry's commitment to improving the lives of individuals experiencing excessive sweating. The International Hyperhidrosis Society (IHhS) is a non-profit organization based in the United States that serves millions of individuals affected by hyperhidrosis.

Major companies operating in the hyperhidrosis treatment market report are Pfizer Inc., AbbVie Inc., Sanofi S.A., AstraZeneca Plc, GSK plc, Teva Pharmaceutical Industries Ltd., Mylan N.V., Cynosure LLC, Ipsen SA, Galderma S.A., Merz Pharma GmbH & Co. KGaA, Daewoong Pharmaceutical Co. Ltd., Supernus Pharmaceuticals Inc, Kaken Pharmaceutical Co Ltd, Avanor Healthcare Ltd., HUGEL Inc., Evolus Inc., Revance Therapeutics Inc., Dermira Inc., Sesderma SL, Miramar Labs Inc., Dermavant Sciences Inc., Theravida Inc., SweatBlock, Brickell Biotech Inc., Fresh Tracks Therapeutics Inc., Advin Health Care Inc, Dermadry Laboratories Inc., Ulthera Inc., Dermata Therapeutics Inc.

North America was the largest region in the hyperhidrosis treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hyperhidrosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the hyperhidrosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hyperhidrosis treatment market consists of revenues earned by entities by providing services such as microwave therapy, iontophoresis, sympathectomy, and sweat gland removal. The market value includes the value of related goods sold by the service provider or included within the service offering. The hyperhidrosis treatment market also includes sales of drysol, xerac AC, glycopyrrolate, benztropine and beta blockers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The primary types of hyperhidrosis treatments include topical treatments, surgical interventions, botulinum toxin A injections, iontophoresis, laser treatments, and other therapeutic approaches. Topical treatments involve the application of agents directly to the skin to address hyperhidrosis symptoms. Surgical treatments may be considered for certain cases, and botulinum toxin A injections are utilized to reduce excessive sweating. Iontophoresis and laser treatments are additional methods used to manage hyperhidrosis. These treatments can be administered through various routes, including oral and injectable, to address specific types of hyperhidrosis, such as axillary, palmar, plantar, and others. Hyperhidrosis treatments are available through different distribution channels, including hospitals, ambulatory surgical centers, retail pharmacies, and online platforms.

The hyperhidrosis treatment market research report is one of a series of new reports that provides hyperhidrosis treatment market statistics, including hyperhidrosis treatment industry global market size, regional shares, competitors with a hyperhidrosis treatment market share, detailed hyperhidrosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the hyperhidrosis treatment industry. This hyperhidrosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 1-3 business days.